Alkermes is a biopharmaceutical company headquartered in Dublin, Ireland, that develops and commercializes pharmaceutical products focused on neurology and psychiatry. The company's marketed portfolio includes ARISTADA and ARISTADA INITIO for schizophrenia treatment, VIVITROL for alcohol dependence and opioid dependence prevention, and LYBALVI, an oral antipsychotic for schizophrenia and bipolar I disorder. These products represent the core of Alkermes' commercial revenue base, with the majority of sales generated in the United States.
Beyond its marketed products, Alkermes maintains a pipeline of clinical and preclinical candidates addressing neurological disorders. The company also operates a proprietary technology platform business, licensing its formulation and delivery technologies to third parties for pharmaceutical development and manufacturing. Collaboration agreements with Janssen Pharmaceuticals entities constitute a significant partnership arrangement for the company.
Alkermes operates across the United States, Ireland, and international markets, with a market capitalization of approximately $5.1 billion. The company was founded in 1987 and is listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $1.43 | $1.47 | -34.1% | |
| 2024 | $2.17 | $2.22 | +3.3% | |
| 2023 | $2.10 | $2.14 | +316.5% | |
| 2022 | $-0.97 | $-0.97 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | $-1.52 | $-1.52 | -623.8% | |
| 2014 | $-0.21 | $-0.21 | -216.7% | |
| 2012 | $0.18 | $0.19 | +118.2% | |
| 2011 | $-0.99 | $-0.99 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-25 | 0001193125-26-068925 | SEC ↗ |
| 2024-12-31 | 2025-02-12 | 0000950170-25-019011 | SEC ↗ |
| 2023-12-31 | 2024-02-21 | 0000950170-24-017883 | SEC ↗ |
| 2022-12-31 | 2023-02-16 | 0001564590-23-002020 | SEC ↗ |
| 2021-12-31 | 2022-02-16 | 0001564590-22-005304 | SEC ↗ |
| 2020-12-31 | 2021-02-11 | 0001564590-21-005593 | SEC ↗ |
| 2019-12-31 | 2020-02-13 | 0001564590-20-004489 | SEC ↗ |
| 2018-12-31 | 2019-02-15 | 0001564590-19-003060 | SEC ↗ |
| 2017-12-31 | 2018-02-16 | 0001520262-18-000016 | SEC ↗ |
| 2016-12-31 | 2017-02-17 | 0001520262-17-000007 | SEC ↗ |